The following transactions have been entered into with related parties:
|
H1 2025 kEUR |
Income from related parties |
Purchases from related parties |
Amounts due from related parties |
Amounts due to related parties |
|
|
|
|
|
|
|
Thalamus AB |
– |
-39 |
– |
-657 |
|
Ferring Group |
10,573 |
– |
966 |
-775 |
|
Monedula AB |
38 |
-339 |
94 |
-10,869 |
|
SVAR Life Science AB |
18 |
– |
– |
– |
|
Nordic Pharma Ltd. |
2 |
– |
– |
– |
|
Limhamn Kajan 37 AB |
– |
-26 |
– |
-819 |
In addition to the information shown in the table above, PolyPeptide Group AG has secured a subordinated credit facility from its main shareholder, Draupnir Holding B.V.
As a result, interest expenses in the amount of kEUR 787 have been incurred during H1 2025. As at 30 June 2025, an amount of kEUR 20,000 was drawn from the credit facility and is accordingly recognized in the consolidated statement of financial position as a non-current liability.
|
H1 2024 kEUR |
Income from related parties |
Purchases from related parties |
Amounts due from related parties |
Amounts due to related parties |
|
|
|
|
|
|
|
Thalamus AB |
– |
-89 |
– |
-765 |
|
Ferring Group |
15,156 |
-117 |
1,006 |
-45 |
|
Monedula AB |
68 |
-671 |
85 |
-11,223 |
|
Amring Pharmaceuticals Inc |
3 |
– |
– |
– |
|
SVAR Life Science AB |
70 |
-1 |
38 |
– |
|
Nordic Pharma Ltd. |
– |
-2 |
– |
– |
|
Limhamn Kajan 37 AB |
– |
-33 |
– |
-140 |
In addition to the information shown in the table above, PolyPeptide Group AG has secured a short-term credit facility from its main shareholder, Draupnir Holding B.V. As a result, interest expenses in the amount of kEUR 1,605 have been incurred during H1 2024. As at 30 June 2024, an amount of kEUR 40,000 was drawn from the credit facility and is accordingly recognized in the consolidated statement of financial position as a current liability.
All disclosed related parties are either related through the Esperante Investments S.à r.l. ownership structure or through managerial control. Esperante Investments S.à r.l. is a higher parent company of the majority shareholder Draupnir Holding B.V.
Purchases from and amounts due to Thalamus AB relate to rental of premises. Income from and amounts due from the Ferring Group relate to sale of goods.
Purchases from Monedula AB relate to the lease of premises. Income and amounts due from Monedula relate to property management fees and recharged improvements to the premises. Amounts due to Monedula AB relate to the financial liability recognized for the lease of premises.
Income from and amounts due from SVAR Life Science AB relates to sale of goods. Purchases from and amounts due to Limhamn Kajan 37 AB relate to rental of premises.
During H1 2025, no provisions for doubtful debt and no write-offs on receivables from related parties were recognized (H1 2024: nil). No guarantees were given or received for any outstanding related party balances (H1 2024: nil).